XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.2
Divestiture of Preclinical Small Molecule Programs (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Mar. 01, 2024
Dec. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items]            
Equity consideration received in the divestiture of small molecule programs (Note 10)         $ 0 $ 15,000
Convertible preferred stock, par value (usd per share)   $ 0.01 $ 0.01   $ 0.01  
Gain from divestiture of small molecule programs     $ 0 $ 0 $ 0 14,537
Tenvie Therapeutics, Inc            
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items]            
Equity consideration received in the divestiture of small molecule programs (Note 10) $ 15,000          
Noncash or part noncash divestiture, milestone payments, to be received     $ 1,200,000   $ 1,200,000  
Future royalties, threshold after first commercial sale     10 years   10 years  
Tenvie Therapeutics, Inc | Series A Preferred Stock            
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items]            
Number of shares converted in simple agreement for future equity (in shares)   15.0        
Convertible preferred stock, par value (usd per share)   $ 0.0001        
Fair value of shares converted in simple agreement for future equity   $ 15,000        
Fair value of investment   $ 15,000 $ 15,000   $ 15,000  
Venture Backed Private Company ("VBPC")            
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items]            
Equity consideration received in the divestiture of small molecule programs (Note 10) $ 15,000          
Gain from divestiture of small molecule programs           $ 14,500